Kite looks all set for a regulatory approval later this year for its CAR-T drug KTE-CI9 after the company published encouraging topline primary results.
Roche’s Mabthera (rituximab) blood cancer and inflammatory diseases drug faces cheaper competition for the first time in Europe after regulators approved a near-copy, or biosimilar, from Ce
If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho